Swiss National Bank Has $54.40 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Swiss National Bank trimmed its stake in Laboratory Co. of America Holdings (NYSE:LH) by 5.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,220 shares of the medical research company’s stock after selling 13,000 shares during the period. Swiss National Bank owned about 0.28% of Laboratory Co. of America worth $54,399,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LH. Great Lakes Advisors LLC increased its stake in Laboratory Co. of America by 675.2% during the fourth quarter. Great Lakes Advisors LLC now owns 27,038 shares of the medical research company’s stock valued at $6,200,000 after acquiring an additional 23,550 shares during the period. Farther Finance Advisors LLC increased its position in shares of Laboratory Co. of America by 122.2% during the fourth quarter. Farther Finance Advisors LLC now owns 3,077 shares of the medical research company’s stock valued at $706,000 after purchasing an additional 1,692 shares during the period. Sequoia Financial Advisors LLC lifted its position in Laboratory Co. of America by 0.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 135,888 shares of the medical research company’s stock worth $31,162,000 after purchasing an additional 475 shares during the period. Inspire Advisors LLC boosted its stake in Laboratory Co. of America by 10.2% during the fourth quarter. Inspire Advisors LLC now owns 3,174 shares of the medical research company’s stock worth $728,000 after buying an additional 295 shares in the last quarter. Finally, River Road Asset Management LLC increased its holdings in Laboratory Co. of America by 3.1% in the 4th quarter. River Road Asset Management LLC now owns 292,784 shares of the medical research company’s stock valued at $67,141,000 after buying an additional 8,687 shares during the period. Institutional investors own 95.94% of the company’s stock.

Insider Transactions at Laboratory Co. of America

In related news, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now directly owns 86,445 shares of the company’s stock, valued at $21,146,175.90. The trade was a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the completion of the sale, the director now owns 12,722 shares of the company’s stock, valued at $2,989,670. This represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,500 shares of company stock worth $3,577,572 in the last quarter. 0.85% of the stock is owned by company insiders.

Laboratory Co. of America Stock Performance

Shares of Laboratory Co. of America stock opened at $239.80 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a 50 day simple moving average of $244.69 and a 200 day simple moving average of $234.04. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The firm has a market cap of $20.07 billion, a P/E ratio of 27.19, a P/E/G ratio of 1.71 and a beta of 1.12.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Sell-side analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.20%. The ex-dividend date was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 32.65%.

Analyst Ratings Changes

Several analysts have recently weighed in on LH shares. Piper Sandler lifted their target price on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. UBS Group decreased their price target on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Jefferies Financial Group increased their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Barclays reduced their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Laboratory Co. of America currently has a consensus rating of “Moderate Buy” and an average price target of $268.38.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.